{"id":"rrx-001-eloop-device","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-related adverse events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"RRx-001 is designed to act as an immunogenic cell death inducer and immune checkpoint modulator that enhances anti-tumor immunity. The eLOOP device is a proprietary delivery/activation platform that optimizes RRx-001's bioavailability and therapeutic effect. Together, they aim to overcome resistance to standard immunotherapies by priming the tumor microenvironment and enhancing T-cell infiltration and activation.","oneSentence":"RRx-001 is a small-molecule immunotherapeutic that works synergistically with the eLOOP device to enhance immune activation and tumor cell death through modulation of immune checkpoints and metabolic pathways.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:52:41.636Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (Phase 3 development)"},{"name":"Potentially checkpoint inhibitor-resistant cancers"}]},"trialDetails":[{"nctId":"NCT05566041","phase":"PHASE3","title":"A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"EpicentRx, Inc.","startDate":"2022-08-01","conditions":"Carcinoma, Small Cell Lung","enrollment":292},{"nctId":"NCT03699956","phase":"PHASE3","title":"RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer","status":"TERMINATED","sponsor":"EpicentRx, Inc.","startDate":"2018-12-24","conditions":"Carcinoma, Small Cell Lung","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RRx-001 + eLOOP Device","genericName":"RRx-001 + eLOOP Device","companyName":"EpicentRx, Inc.","companyId":"epicentrx-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RRx-001 is a small molecule being studied in combination with the eLOOP Device for the treatment of Small Cell Lung Cancer. RRx-001 is being evaluated in a Phase 3 clinical trial, REPLATINUM, in comparison to a platinum doublet chemotherapy regimen.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}